Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
841-860 of 998 trials

Advanced Liver Cancer: CS1003 with Lenvatinib

We are studying a new treatment combined with lenvatinib for people with advanced liver cancer. The trial compares this combination to a placebo with lenvatinib to see which is more effective and safe.

Unresectable Advanced Liver Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHepatologyOncology

TOASST Study: Comparing Steroid Withdrawal Methods

We are studying whether stopping glucocorticoids suddenly is as safe as tapering them for patients with inflammatory disorders. This research may help improve treatment strategies and patient outcomes.

Inflammatory or Autoimmune Disorders>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Bladder Cancer: V940 and BCG Combination Study

We are investigating whether a new treatment, V940, combined with BCG can improve outcomes for people with high-risk non-muscle invasive bladder cancer compared to BCG alone. This study will also assess the safety of all treatment options.

Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Statin Therapy for Frail Older Adults After Stroke

We are studying whether starting statin medication helps frail individuals aged 70 and older who have had a recent stroke or transient ischemic attack. The goal is to see if it improves heart health and quality of life.

Ischemic Stroke and Transient Ischemic Attack>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Rheumatoid Arthritis: CIT-013 Study

We are investigating a new medication, CIT-013, for people with moderately active rheumatoid arthritis. The study aims to see if it helps reduce disease activity and to understand its safety.

Moderately Active Rheumatoid Arthritis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Multiple Myeloma: New Treatment Combinations

We are studying a combination of new medications for people with newly diagnosed multiple myeloma who can undergo a transplant. The goal is to evaluate their safety and effectiveness in improving treatment outcomes.

Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Recombinant Factor VIIa for Acute Hemorrhagic Stroke

We are studying whether giving a new treatment quickly after a bleeding stroke can improve recovery for patients. This trial focuses on those who have had spontaneous bleeding in the brain and aims to measure their functional outcomes.

Hemorrhagic Stroke>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteHematologyNeurology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Chronic Pain After Mastectomy: Comparing Treatments

We are studying the effectiveness of Serratus Plane Block, capsaicin, and botulinum toxin type A for managing chronic neuropathic pain after mastectomy. This trial aims to find out which treatment offers better pain relief for those not helped by standard therapies.

Post-Mastectomy Pain Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOncology

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Congenital Nephrogenic Diabetes Insipidus: Fluconazole Study

We are testing whether fluconazole can help people with congenital nephrogenic diabetes insipidus reduce excessive urination and improve their quality of life. This study focuses on patients with a specific AVPR2 gene mutation.

Congenital Nephrogenic Diabetes Insipidus≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrology

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: TAK-881 vs. HYQVIA

We are comparing two medications to see if TAK-881 works similarly to HYQVIA in adults with CIDP. This study may help determine the best treatment options for managing this condition.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Chronic Obstructive Pulmonary Disease: Tezepelumab Study

We are investigating whether tezepelumab can help adults with moderate to very severe COPD experience fewer flare-ups and improve their lung function and quality of life compared to a placebo.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology

Nasopharyngeal Cancer: Nivolumab Treatment Study

We are studying the effectiveness of Nivolumab for patients with nasopharyngeal cancer who have progressed after chemotherapy. We also want to understand how safe this treatment is for these patients.

Nasopharyngeal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Duchenne Muscular Dystrophy: ENTR-601-45 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Duchenne Muscular Dystrophy6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

ALK-Positive Advanced Lung Cancer: NVL-655 vs. Alectinib

We are studying a new medication, NVL-655, for patients with advanced ALK-positive lung cancer who haven't been treated before. The goal is to see if it works better and is safer than the current standard treatment, alectinib.

Advanced ALK-positive Non-Small Cell Lung CancerConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Severe Asthma: Dupilumab Treatment Study

We are investigating how Dupilumab affects mucus buildup and immune responses in patients with severe asthma. This study aims to improve understanding of asthma management and treatment options.

Severe Asthma>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

Kidney Transplant: Ravulizumab Study

We are testing Ravulizumab in adults at high risk of delayed graft function after kidney transplantation. The goal is to see if it helps improve kidney function and reduces the need for dialysis.

Delayed Graft Function after Kidney Transplantation1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNephrology

Duchenne Muscular Dystrophy: ENTR-601-44 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and how it affects muscle function. Participants will receive either the treatment or a placebo in a controlled setting.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology